Waldenstrom's Macroglobulinemia Research Waldenstrom's Macroglobulinemia RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Inflammation is predictive of outcome in Waldenstr öm macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study
Haematologica. 2023 Aug 16. doi: 10.3324/haematol.2023.283141. Online ahead of print.NO ABSTRACTPMID:37584289 | DOI:10.3324/haematol.2023.283141 (Source: Haematologica)
Source: Haematologica - August 16, 2023 Category: Hematology Authors: Pierre-Edouard Debureaux Nathalie Forgeard Dikelele Elessa St éphanie Harel Laurent Frenzel Bruno Royer Alexis Talbot Sylvain Choquet Frederic Davi Florence Nguyen-Khac Wendy Cuccuini Morgane Cheminant Clotilde Bravetti Gregory Lazarian Sophie Kaltenbach Source Type: research

Inflammation is predictive of outcome in Waldenstr öm macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study
Haematologica. 2023 Aug 17. doi: 10.3324/haematol.2023.283141. Online ahead of print.NO ABSTRACTPMID:37584289 | DOI:10.3324/haematol.2023.283141 (Source: Haematologica)
Source: Haematologica - August 16, 2023 Category: Hematology Authors: Pierre-Edouard Debureaux Nathalie Forgeard Dikelele Elessa St éphanie Harel Laurent Frenzel Bruno Royer Alexis Talbot Sylvain Choquet Frederic Davi Florence Nguyen-Khac Wendy Cuccuini Morgane Cheminant Clotilde Bravetti Gregory Lazarian Sophie Kaltenbach Source Type: research

Inflammation is predictive of outcome in Waldenstr öm macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study
Haematologica. 2023 Aug 17. doi: 10.3324/haematol.2023.283141. Online ahead of print.NO ABSTRACTPMID:37584289 | DOI:10.3324/haematol.2023.283141 (Source: Haematologica)
Source: Haematologica - August 16, 2023 Category: Hematology Authors: Pierre-Edouard Debureaux Nathalie Forgeard Dikelele Elessa St éphanie Harel Laurent Frenzel Bruno Royer Alexis Talbot Sylvain Choquet Frederic Davi Florence Nguyen-Khac Wendy Cuccuini Morgane Cheminant Clotilde Bravetti Gregory Lazarian Sophie Kaltenbach Source Type: research

Inflammation is predictive of outcome in Waldenstr öm macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study
Haematologica. 2023 Aug 17. doi: 10.3324/haematol.2023.283141. Online ahead of print.NO ABSTRACTPMID:37584289 | DOI:10.3324/haematol.2023.283141 (Source: Haematologica)
Source: Haematologica - August 16, 2023 Category: Hematology Authors: Pierre-Edouard Debureaux Nathalie Forgeard Dikelele Elessa St éphanie Harel Laurent Frenzel Bruno Royer Alexis Talbot Sylvain Choquet Frederic Davi Florence Nguyen-Khac Wendy Cuccuini Morgane Cheminant Clotilde Bravetti Gregory Lazarian Sophie Kaltenbach Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia
Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progressio...
Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research